Status:
RECRUITING
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Lead Sponsor:
Shen Chun-Hong
Conditions:
Autoimmune Encephalitis
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Eligibility:
All Genders
18-100 years
Brief Summary
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) e...
Detailed Description
In this prospective study, the investigators are aiming to recruit newly diagnosed patients with anti-LGI1 encephalitis. At the acute stage and during the follow-up, some routine and advanced paraclin...
Eligibility Criteria
Inclusion
- Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis.
- Newly diagnosed, and during the acute stage before study enrollment.
- Sign the informed consent form.
Exclusion
- with the diagnosis of epilepsy, stroke, cerebral trauma, and/or other nervous system disease prior to the onset of encephalitis.
- with coexisting antibodies, such as anti-contactin-associated protein 2 (CASPR2) antibody.
- Lost to follow-up.
Key Trial Info
Start Date :
May 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2032
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06173076
Start Date
May 18 2022
End Date
December 31 2032
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China